Sun Pharma Advanced Research Company Limited (SPARC.NS) Bundle
A Brief History of Sun Pharma Advanced Research Company Limited
Sun Pharma Advanced Research Company Limited (SPARC) was established in 2007 as a subsidiary of Sun Pharmaceutical Industries Limited. The company focuses heavily on research and development in the pharmaceutical sector, particularly in innovative drug delivery systems and formulations.
In the fiscal year 2022, SPARC reported total revenue of ₹137.5 crore, marking a significant increase of 18% compared to the previous fiscal year. The net loss for the same period was reported at ₹72.2 crore.
SPARC’s R&D activities are primarily centered in India, with facilities in Ahmedabad and Mumbai. In 2015, the company initiated a research partnership with the US-based pharmaceutical company, AbbVie, to develop novel therapies focusing on oncology and autoimmune diseases.
In recent years, SPARC has made strides in clinical trials. As of October 2023, the company is conducting several clinical trials for its innovative products, with a notable focus on the oral formulation of Mucopolysaccharidosis Type I (MPS I). The company has announced that trials for this drug are in Phase 3, expected to conclude by mid-2024.
The following table summarizes key financial metrics and important milestones in SPARC's journey:
| Year | Total Revenue (₹ crore) | Net Profit/Loss (₹ crore) | Market Capitalization (₹ crore) | Key Milestones |
|---|---|---|---|---|
| 2017 | 100.5 | -45.0 | 1,200 | Public listing on NSE |
| 2018 | 130.0 | -38.5 | 1,800 | Launched two new dermatology products |
| 2019 | 155.0 | -25.0 | 2,200 | Partnership with AbbVie for drug development |
| 2020 | 90.0 | -60.0 | 1,400 | Restructuring led to operational efficiencies |
| 2021 | 116.5 | -20.0 | 1,600 | Initiated Phase 2 trials for MPS I drug |
| 2022 | 137.5 | -72.2 | 1,900 | Entered Phase 3 trials for MPS I |
As of the latest updates, SPARC continues to invest significantly in R&D, allocating around 20% of its revenue towards research initiatives. The company aims to enhance its product portfolio with a focus on specialty products, including areas such as dermatology and chronic diseases.
Under the leadership of Managing Director Dr. Anil R. Kumar, SPARC has made notable advancements in developing targeted therapies. The company’s strategy relies heavily on collaborations with global pharmaceutical giants, ensuring access to expertise and resources. In the context of market positioning, SPARC has been navigating challenging conditions with a view to expanding its international footprint.
SPARC is actively pursuing regulatory approvals in key markets and is optimistic about potential product launches in the next few years, specifically targeting large unmet medical needs in chronic disease management.
A Who Owns Sun Pharma Advanced Research Company Limited
Sun Pharma Advanced Research Company Limited (SPARC) operates as a subsidiary of Sun Pharmaceutical Industries Ltd., which is one of India's largest pharmaceutical companies. As of October 2023, Sun Pharmaceutical Industries Ltd. holds approximately 75.10% of the total outstanding shares of SPARC.
The shareholding structure of Sun Pharma Advanced Research Company is composed of various institutional and retail investors, with significant holdings distributed as follows:
| Shareholder Type | Percentage Ownership | Number of Shares |
|---|---|---|
| Sun Pharmaceutical Industries Ltd. | 75.10% | 42,075,000 |
| Foreign Institutional Investors (FIIs) | 10.00% | 5,600,000 |
| Domestic Institutional Investors (DIIs) | 5.00% | 2,800,000 |
| Individual Investors | 9.90% | 5,500,000 |
The public float of SPARC as of the latest reporting is approximately 24.90%. This includes a combination of domestic and foreign institutional investments, which have shown increasing interest in the pharmaceutical sector due to the robust growth potential.
In terms of market performance, SPARC's stock price stood at approximately ₹256 as of the latest market close, reflecting a year-to-date gain of approximately 15%. The company reported a market capitalization of around ₹1,780 crores (approximately $220 million).
SPARC's financial performance in the last fiscal year also displayed promising growth metrics. The company's revenue for FY 2022-23 was reported at approximately ₹384 crores (approximately $46 million), with a net profit margin of around 12%.
Furthermore, during recent financial disclosures, SPARC announced a research and development expenditure of approximately ₹50 crores in the last quarter, signifying a strong commitment to innovation and development of new therapeutic areas.
Overall, SPARC's ownership structure, combined with its solid financial statistics, paints a picture of a robust organization within the pharmaceutical sector, bolstered by the backing of its parent company, Sun Pharmaceutical Industries Ltd.
Sun Pharma Advanced Research Company Limited Mission Statement
Sun Pharma Advanced Research Company Limited (SPARC) operates with a mission to enhance the quality of life through innovative research and development in the pharmaceutical sector. Their commitment focuses on developing new chemical entities (NCEs), complex generics, and drug delivery systems.
The company emphasizes a culture of excellence, integrity, and collaboration in its approach to research activities. SPARC aims to leverage its scientific capabilities and innovative spirit to bring comprehensive solutions across various therapeutic areas.
Key Components of the Mission Statement
- Innovation: Constantly striving to develop breakthrough treatments that benefit patients globally.
- Quality: Ensuring the highest quality standards in research and drug development.
- Collaboration: Partnering with other organizations and institutions to accelerate the development of new drugs.
Financial Performance
As of the latest financial year ending March 2023, SPARC reported total revenue of ₹1,053.3 million, which demonstrates a year-over-year growth of 22%. The net profit for the same period reached ₹152.6 million, with an increase in profit margin to 14.5% compared to 10.8% in the previous fiscal year.
| Financial Metric | FY 2023 | FY 2022 | Growth (%) |
|---|---|---|---|
| Total Revenue (₹ million) | 1,053.3 | 864.8 | 22 |
| Net Profit (₹ million) | 152.6 | 93.5 | 63.2 |
| Profit Margin (%) | 14.5 | 10.8 | 3.7 |
Research and Development Focus
SPARC allocates a significant portion of its resources to R&D, with R&D expenditure for FY 2023 amounting to ₹329 million, representing approximately 31% of total revenue. The company is engaged in multiple projects across therapeutic areas including oncology, dermatology, and neurology.
Recent Achievements
- New Drug Approvals: SPARC received FDA approval for three new products in the last fiscal year.
- Collaborations: Entered strategic collaborations with globally recognized partners, enhancing their R&D capabilities.
- Clinical Trials: Successfully completed Phase II clinical trials for key drug candidates aimed at treating chronic illnesses.
Market Position
SPARC holds a strong position in the Indian pharmaceuticals market, ranking among the top 10 companies for innovative drug development. As of September 2023, SPARC's market capitalization stood at approximately ₹49 billion.
Conclusion on Mission Statement Impact
The mission statement of Sun Pharma Advanced Research Company Limited not only reflects its commitment to quality and innovation but also serves as a guiding principle for its strategic direction and operational activities. This alignment is evident in the company's consistent financial growth and advancement in research initiatives.
How Sun Pharma Advanced Research Company Limited Works
Sun Pharma Advanced Research Company Limited (SPARC) operates as a research and development arm within the Sun Pharmaceutical Industries Limited group. SPARC is focused on developing differentiated pharmaceutical products, particularly in complex generics and specialty formulations.
The company primarily engages in the identification and development of novel drug delivery systems, and it leverages its specialized expertise in areas like oncology, neurology, and dermatology. As of the fiscal year ended March 2023, SPARC reported a total revenue of ₹211.5 crore, marking an increase from ₹182.1 crore in the previous fiscal year.
In its latest financial results for Q1 FY2024, SPARC posted a net profit of ₹19.3 crore, compared to a net profit of ₹6.2 crore in Q1 FY2023. This growth is largely attributed to successful new product launches and the ramp-up of existing product sales.
| Fiscal Year | Total Revenue (₹ Crores) | Net Profit (₹ Crores) | R&D Expense (₹ Crores) | EPS (₹) |
|---|---|---|---|---|
| 2021 | ₹140.5 | ₹4.1 | ₹40.2 | ₹1.25 |
| 2022 | ₹182.1 | ₹12.3 | ₹45.7 | ₹2.20 |
| 2023 | ₹211.5 | ₹19.3 | ₹50.4 | ₹3.35 |
SPARC invests significantly in R&D, with an allocation of ₹50.4 crore for the fiscal year 2023. The company has established multiple collaborations and licensing agreements to enhance its research capabilities and market reach. Recent collaborations include a partnership with a major US-based pharmaceutical firm to develop innovative therapies in oncology.
As part of its operational framework, SPARC emphasizes regulatory compliance and quality assurance throughout its product lifecycle. The company’s manufacturing facilities comply with global standards, including those set by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA).
In terms of market presence, SPARC has a robust pipeline that includes over 25 product candidates in various stages of development, focusing on both generic and innovative drug markets. The company aims to leverage its existing portfolio while exploring new market opportunities through continued investment in research.
In the stock market, SPARC has shown considerable resilience. As of October 2023, the shares of SPARC were trading at approximately ₹276.50, reflecting a year-to-date growth of around 22%.
SPARC's strategic direction focuses on developing high-value products and expanding its global footprint. The company continues to monitor the shifting landscape of the pharmaceutical industry, adapting its research and product development strategies accordingly.
How Sun Pharma Advanced Research Company Limited Makes Money
Sun Pharma Advanced Research Company Limited (SPARC) generates revenue primarily through its focus on the development and commercialization of specialty pharmaceuticals and drug delivery systems. As of FY 2023, SPARC reported total revenues of approximately ₹948 crore (around $115 million), a significant increase from ₹836 crore in FY 2022.
The company derives its income from multiple segments, including:
- Research and Development (R&D): SPARC invests heavily in R&D, with an expenditure of about ₹451 crore in FY 2023.
- Licensing Agreements: SPARC has entered into various licensing deals, contributing to revenue streams. The company reported that licensing agreements accounted for 20% of total revenues in the last fiscal year.
- Product Sales: The sales of developed products, including generics and specialty drugs, provide substantial earnings. The estimated sales from these products were around ₹520 crore in FY 2023.
SPARC focuses on niche areas such as dermatology, oncology, and ophthalmology. The following table illustrates the company’s key revenue streams in FY 2023:
| Revenue Stream | Amount (₹ crore) | Percentage of Total Revenue |
|---|---|---|
| Research and Development | 451 | 48% |
| Licensing Agreements | 189 | 20% |
| Product Sales | 520 | 55% |
| Other Income | 45 | 5% |
In terms of market strategy, SPARC emphasizes innovative drug delivery technologies and partnerships with established pharmaceutical companies for clinical trials and market access. The company has seen increased collaboration with Sun Pharmaceutical Industries Ltd, which has been instrumental in the commercialization of products developed by SPARC.
Additionally, SPARC aims to expand its international presence, especially in regulated markets such as the US and Europe. In FY 2023, international sales climbed to approximately ₹340 crore, contributing 36% to overall revenue.
For FY 2023, the profitability margin for SPARC was around 15%, reflecting a stable growth trajectory compared to 12% in FY 2022. The company's focus on high-margin specialty products offers a strategic advantage in a competitive market.
SPARC has an active pipeline, with over 10 products in various stages of clinical trials as of October 2023. The company has invested significantly in the development of these products, with a projected investment of ₹300 crore for the next fiscal year to enhance R&D capabilities and accelerate product development timelines.
Sun Pharma Advanced Research Company Limited (SPARC.NS) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.